The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

Described herein are methods and compositions relating to the treatment of e.g., cancer, autoimmune disease, immune deficiency, and/or neurodegenerative disease. In some embodiments, the methods of treatment relate to administering a compound as described herein. In some embodiments, the subject treated according to the methods described herein is a subject determined to have an increased level of DNA damage.

Described herein are methods and compositions relating to the treatment of e.g., cancer, autoimmune disease, immune deficiency, and/or neurodegenerative disease. In some embodiments, the methods of treatment relate to administering a compound as described herein. In some embodiments, the subject treated according to the methods described herein is a subject determined to have an increased level of DNA damage.

Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

The invention relates to a compound of the formula (I) Ar(NHSO.sub.2Ar.sup.1)l(SO.sub.2NHAr.sup.1).sub.m(NHC(O)NHAr.sup.2).sub.n (I), wherein l and m independently of one another are 0, 1, 2, 3, and/or 4 and the sum of l+m is equal to or more than 1, n is 2, 3, 4, or 5, Ar is a benzol group which is substituted (l+m+n) times, Ar.sup.1 is an unsubstituted or substituted aromatic group, and Ar.sup.2 is an unsubstituted or substituted phenyl group or a benzoyl group. The invention also relates to a heat-sensitive recording material comprising a carrier substrate and a heat-sensitive color-forming layer which contains at least one color former and at least said color developer.

The invention relates to a compound of the formula (I) Ar(NHSO.sub.2Ar.sup.1)l(SO.sub.2NHAr.sup.1).sub.m(NHC(O)NHAr.sup.2).sub.n (I), wherein l and m independently of one another are 0, 1, 2, 3, and/or 4 and the sum of l+m is equal to or more than 1, n is 2, 3, 4, or 5, Ar is a benzol group which is substituted (l+m+n) times, Ar.sup.1 is an unsubstituted or substituted aromatic group, and Ar.sup.2 is an unsubstituted or substituted phenyl group or a benzoyl group. The invention also relates to a heat-sensitive recording material comprising a carrier substrate and a heat-sensitive color-forming layer which contains at least one color former and at least said color developer.

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: ##STR00001##
wherein Q is selected from O, S and Se; J is S or Se; W.sup.1 and W.sup.2, when present, are independently selected from N and C; R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen, C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, C.sub.2-C.sub.12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W.sup.1 and W.sup.2 is present and is a nitrogen atom and when R.sup.1 or R.sup.2 are cyclic then the respective W.sup.1 or W.sup.2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: ##STR00001##
wherein Q is selected from O, S and Se; J is S or Se; W.sup.1 and W.sup.2, when present, are independently selected from N and C; R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen, C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, C.sub.2-C.sub.12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W.sup.1 and W.sup.2 is present and is a nitrogen atom and when R.sup.1 or R.sup.2 are cyclic then the respective W.sup.1 or W.sup.2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.